Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Hairy cell leukaemia, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Variant HCL and IGHV4-34 disease respond poorly to purine analogues.
Infection risk during induction neutropenia.
Whether MRD eradication should be a treatment goal.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Relapsed/refractory hairy cell leukaemia after ≥2 systemic therapies including a purine analogue
First CD22 immunotoxin; withdrawn from the US market in 2023 for commercial reasons.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.